The product that will result from this SBIR is a small molecule drug therapy for Alzheimer's Disease (AD) that works by inhibiting amyloid precursor protein synthesis. AD accounts for two-thirds of all dementia, afflicting more than 26 million people worldwide, and in excess of 4 million Americans. The amyloid hypothesis of AD proposes that increased levels of amyloid-beta (Ab) peptides in the brain, possibly in their aggregated form, mediate a cascade of events leading to neuronal dysfunction, degeneration and clinical dementia. At present, currently approved therapies are considered to be primarily symptomatic. Although a large number of potentially disease-modifying therapeutic strategies are in current development, primarily focused on Ab and tau, the primary constituents of amyloid plaques and NFTs, respectively, none has been approved for AD treatment. [+]-Phenserine-tartrate is an experimental drug that has been exclusively licensed by QR Pharma. In both cell cultures and in animals [+]-phenserine-tartrate has been found to lower the rate of amyloid precursor protein synthesis. APP mRNA is efficiently translated and can be regulated at the level of its 5'-untranslated region (5'-UTR). [+]-phenserine-tartrate acts to lower the rate of APP synthesis via this 5'-UTR, reducing APP protein as well as Ab (1-40 and 1-42) by up to 50% in neuronal cultures and mice following both i.p. and oral administration. [+]-Phenserine-tartrate has been successfully developed through FDA required preclinical studies, has been FDA-approved for human use, and has begun Phase 1 clinical trials (single and repeated dosing). [+]- Phenserine-tartrate was well tolerated in both rodents and dogs in preclinical toxicological studies following oral administration and, likewise, was well tolerated in healthy elderly volunteers after oral dosing. A comparison of plasma concentrations achieved in humans following a well-tolerated dose with Ab-lowering concentrations in rodents suggests that effective concentrations can be achieved in humans. Collectively, these data indicate that [+]-phenserine-tartrate is an orally bioavailable small drug that readily enters the brain and can effectively lower Ab without toxicity. In all species, plasma Posiphen disappeared with a half-life of 2 to 4 hours following oral dosing, generating the major metabolite, [+]-N1,N8-bisnorposiphen, via its [+]-N1- and [+]-N8-norposiphen intermediates. These intermediates have been found to possess anticholinesterase activity, and since they achieve substantially greater concentrations than the parent drug, require to be characterized and optimized to support continued assessment of activities in the next phase of clinical studies in AD subjects. , ,
Public Health Relevance: The product that will result from this SBIR is a small molecule drug therapy for Alzheimer's Disease that works by inhibiting a molecular cause of the disease. Alzheimer's Disease accounts for two-thirds of all dementia. Although a number of potentially disease-modifying therapeutic strategies are in current development, none has so far been approved.
Thesaurus Terms: 1,3-Dimethyl-5-Aminoadamantane;1-Amino-3,5-Dimethyladamantane;5' Untranslated Regions;5'utr;App Secretase;Abbreviations;Abscission;Accounting;Acetylcholine Hydrolase;Acetylcholinesterase;Acetylcholinesterase Inhibitors;Acute;Acylcholine Acylhydrolase;Acylcholineacylhydrolase;Administration, Oral;Affect;Aged 65 And Over;Aging;Alzheimer;Alzheimer Beta-Protein;Alzheimer Disease;Alzheimer Sclerosis;Alzheimer Syndrome;Alzheimer's;Alzheimer's Disease;Alzheimer's Amyloid;Alzheimers Dementia;Alzheimers Disease;Amentia;American;Amyloid;Amyloid A4 Protein Precursor;Amyloid Alzeheimer's Dementia Amyloid Protein;Amyloid Beta-Peptide;Amyloid Fibril Protein (Alzheimer's);Amyloid Plaques;Amyloid Precursor Protein Secretase;Amyloid Protein A4;Amyloid Protein Precursor;Amyloid Substance;Amyloid Beta-Protein;Amyloid Beta-Protein Precursor;Amyloid Beta-Protein, Alzheimer's;Amyloid Deposition;Animals;Anti-Cholinesterases;Anticholinesterase Agents;Anticholinesterase Drugs;Anticholinesterases;Behavior;Bioavailable;Blood Plasma;Blotting, Western;Brain;Canine Species;Canis Familiaris;Cell Culture Techniques;Cell/Tissue, Immunohistochemistry;Cells;Cessation Of Life;Cholinesterase Inhibitors;Cholinesterases;Clinical;Clinical Research;Clinical Study;Clinical Trials, Phase I;Cognition;Data;Death;Degenerative Diseases, Nervous System;Degenerative Neurologic Disorders;Dementia;Dementia, Alzheimer Type;Dementia, Primary Senile Degenerative;Dementia, Senile;Dependence;Deterioration;Development;Disease;Disorder;Dogs;Dose;Drug Administration, Oral;Drug Delivery;Drug Delivery Systems;Drug Design;Drug Targeting;Drug Targetings;Drug Therapy;Drugs;Elisa;Early-Stage Clinical Trials;Elderly;Elderly, Over 65;Encephalon;Encephalons;Enzyme-Linked Immunosorbent Assay;Event;Excision;Exposure To;Extirpation;Fda Approved;Genetic Alteration;Genetic Change;Genetic Translation;Genetic Defect;Glutamates;Goals;Half-Life;Half-Lifes;Hour;Human;Human, General;Ihc;Immunohistochemistry;Immunohistochemistry Staining Method;Inhibitors, Acetylcholinesterase;Institutes;L-Glutamate;Licensing;Mt-Bound Tau;Mammals, Dogs;Mammals, Mice;Mammals, Rodents;Man (Taxonomy);Man, Modern;Mediating;Medication;Memantin;Memantine;Messenger Rna;Mice;Molecular;Murine;Mus;Mutation;N-Phenylcarbamoyl Eseroline;N-Phenylcarbamoyleseroline;Nerve Cells;Nerve Transmitter Substances;Nerve Unit;Nervous System, Brain;Neural Cell;Neuritic Plaques;Neuroblastoma;Neuroblastoma (Schwannian Stroma-Poor);Neurocyte;Neurodegenerative Diseases;Neurodegenerative Disorders;Neurofibrillary Tangles;Neurologic Degenerative Conditions;Neurologic Diseases, Degenerative;Neuronal Dysfunction;Neurons;Neurotransmitters;Oral;Oral Administration;Parents;Patient Care;Patient Care Delivery;Peptide Biosynthesis, Ribosomal;Pharmaceutic Preparations;Pharmaceutical Preparations;Pharmacotherapy;Phase;Phase 1 Clinical Trials;Phase I Clinical Trials;Phase I Study;Plasma;Population;Primary Senile Degenerative Dementia;Protein Biosynthesis;Protein Biosynthesis, Ribosomal;Protein Synthesis, Ribosomal;Proteins;Rna, Messenger;Receptor Protein;Recovery;Removal;Research;Reticuloendothelial System, Serum, Plasma;Rodent;Rodentia;Rodentias;Sbir;Sbirs (R43/44);Saline;Saline Solution;Sampling;Senescence;Senile Plaques;Serum, Plasma;Small Business Innovation Research;Small Business Innovation Research Grant;Surgical Removal;Tartrates;Therapeutic;Time;Toxic Effect;Toxicities;Transgenic Mice;Translating;Translatings;Tricyclo(3.3.1.13,7)Decan-1-Amine, 3,5-Dimethyl-;Western Blotting;Western Blottings;Western Immunoblotting;Work;A Beta Peptide;Abeta;Acetylcholine Acetylhydrolase;Acetylcholineesterase Inhibition;Acetylcholineesterase Inhibitor;Advanced Age;Amyloid Beta;Amyloid Beta Plaque;Amyloid Pathology;Amyloid Precursor Protein;Amyloid-B Plaque;Amyloid-B Protein;Base;Beta Amyloid Fibril;Biomarker;Canine;Choline Esterase I;Choline Esterase Ii;Cholinergic;Clinical Relevance;Clinically Relevant;Cored Plaque;Cost;Dementia Of The Alzheimer Type;Design;Designing;Diffuse Plaque;Disease/Disorder;Domestic Dog;Drug/Agent;Economic Impact;Efficacy Trial;Elders;Familial Alzheimer Disease;Familial Alzheimer Disease (Fad);Gene Product;Genome Mutation;Geriatric;Inhibitor;Inhibitor/Antagonist;Intraoral Drug Delivery;Language Translation;Late Life;Later Life;Mrna;Mrna Leader Sequences;Mrna Translation;Microtubule Associated Protein Tau;Microtubule Bound Tau;Microtubule-Associated Protein Tau;Microtubule-Bound Tau;Mouse Model;Neurodegenerative Illness;Neurofibrillary Degeneration;Neurofibrillary Lesion;Neurofibrillary Pathology;Neuronal;Neurotoxic;Older Adult;Older Person;Phase 1 Study;Phase 1 Trial;Phase I Trial;Phenserine;Pre-Clinical;Preclinical;Preclinical Study;Presenilin;Prevent;Preventing;Primary Degenerative Dementia;Protein Blotting;Protein Synthesis;Protocol, Phase I;Public Health Relevance;Receptor;Resection;Secretase;Senescent;Senile Dementia Of The Alzheimer Type;Senior Citizen;Small Molecule;Social;Soluble Amyloid Precursor Protein;Tangle;Tau;Tau Proteins;Tau Factor;Volunteer
